Fosamprenavir Calcium
Phase 2Small molecule
Fosamprenavir Calcium is one of 7 small molecule programs targeting Laryngopharyngeal Reflux. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Laryngopharyngeal Reflux
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Protonix
WWyeth-Lederle Vaccines
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Zantac 150
CChattem
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Fosamprenavir Calcium
MMedical College of Wisconsin
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fosamprenavir Calcium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMedical College of Wisconsin